Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Turning off the genetic switch to its respiratory system might finally eliminate the bacteria behind tuberculosis.

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...

So, even via the more modest predictions, people will be able to double their longevity. When you reach 100 years old, you ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Utilizing the gene-editing technology CRISPR, researchers have found a way to combat chemoresistance in lung cancer cells, restoring hope for patients. Shannon Horning/ SciTech Editor For patients ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...